**Zephyr AI精准医疗AI算法公司完成1.11亿美元A轮融资**
北京——Zephyr AI，一家专注于开发高效且可解释的人工智能技术以推动精准医疗的初创公司，今日宣布成功完成了一轮1.11亿美元的A轮融资。此轮融资由知名投资机构Revolution Growth领投，同时获得了制药巨头礼来公司、社会企业家Jeff Skoll以及EPIQ Capital Group等知名投资者的积极参与。
Zephyr AI的核心业务是利用人工智能技术，为医疗行业提供精准的诊断和治疗方案，以改善患者护理并优化医疗决策。其创新的AI算法旨在加速医疗数据的分析，帮助医生和研究人员更快地识别疾病模式，从而实现更个性化、更精准的医疗服务。
Revolution Growth的管理合伙人表示，他们对Zephyr AI的前景充满信心，认为该公司在AI驱动的精准医疗领域具有巨大的潜力。礼来公司的投资则表明制药行业对AI技术在药物研发和临床试验中的应用日益增长的兴趣。
Zephyr AI的首席执行官在评论此次融资时表示，这笔资金将用于进一步研发其AI技术，扩大团队规模，并加速产品在全球医疗市场的推广。他强调，公司的目标是通过可解释的人工智能解决方案，打破医疗领域的数据壁垒，提升医疗服务的效率和质量。
此次A轮融资的成功，不仅为Zephyr AI的未来发展注入了强大动力，也标志着精准医疗领域与人工智能技术融合的又一重要里程碑。随着技术的不断进步，Zephyr AI有望引领医疗行业进入一个更加智能化、个性化的时代。
英语如下：
**”Zephyr AI Secures $110M in Funding, Pioneering a New Chapter for Precision Medicine with AI”**
Keywords: Zephyr AI, precision medicine, Series A funding
News Content:
**Beijing – Zephyr AI, a startup specializing in the development of efficient and explainable AI technologies for precision medicine, has announced the successful completion of a $110 million Series A funding round.**
The round was led by prominent investment firm Revolution Growth, with significant participation from pharmaceutical giant Eli Lilly, social entrepreneur Jeff Skoll, and EPIQ Capital Group, among other notable investors.
Zephyr AI’s core business revolves around leveraging AI to provide the healthcare industry with accurate diagnostic and treatment solutions, enhancing patient care and optimizing medical decision-making. Its innovative AI algorithms aim to accelerate the analysis of medical data, enabling doctors and researchers to identify disease patterns more rapidly, thus facilitating more personalized and precise healthcare services.
The managing partner at Revolution Growth expressed confidence in Zephyr AI’s prospects, highlighting the company’s significant potential in the AI-driven precision medicine field. Eli Lilly’s investment underscores the pharmaceutical industry’s growing interest in AI applications for drug development and clinical trials.
Commenting on the funding, Zephyr AI’s CEO stated that the capital will be allocated to further develop their AI technology, expand the team, and accelerate product rollouts in global healthcare markets. He emphasized the company’s goal of breaking down data barriers in healthcare through explainable AI solutions, enhancing the efficiency and quality of services.
This successful Series A funding not only fuels Zephyr AI’s future growth but also signifies another significant milestone in the convergence of precision medicine and AI technology. As advancements continue, Zephyr AI is poised to steer the healthcare industry towards a more intelligent and individualized era.
【来源】https://www.businesswire.com/news/home/20240312475536/en/Zephyr-AI-Raises-111-Million-in-Series-A-Financing
Views: 1